292 related articles for article (PubMed ID: 22194016)
1. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
Sun WJ; Zhou X; Zheng JH; Lu MD; Nie JY; Yang XJ; Zheng ZQ
Acta Biochim Biophys Sin (Shanghai); 2012 Jan; 44(1):80-91. PubMed ID: 22194016
[TBL] [Abstract][Full Text] [Related]
2. Histone post-translational modification: from discovery to the clinic.
Thomas NR
IDrugs; 2006 Jun; 9(6):398-401. PubMed ID: 16752306
[No Abstract] [Full Text] [Related]
3. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.
Simon RP; Robaa D; Alhalabi Z; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1249-70. PubMed ID: 26701186
[TBL] [Abstract][Full Text] [Related]
4. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
6. [A new target of cancer therapy: advances in the study of histone deacetylase].
Liu AL; Long J; Wang N; Du GH
Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262
[No Abstract] [Full Text] [Related]
7. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
9. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
10. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
11. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
13. Histone deacetylase inhibitors: anticancer compounds.
Smith KT; Workman JL
Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
Meng F; Sun G; Zhong M; Yu Y; Brewer MA
Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
[TBL] [Abstract][Full Text] [Related]
15. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
16. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
18. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
Shimazu T; Horinouchi S; Yoshida M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
[No Abstract] [Full Text] [Related]
19. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
Yang XJ; Seto E
Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
[TBL] [Abstract][Full Text] [Related]
20. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
